Cholesgen Entered into a Drug Discovery Collaboration and Licensing Option Agreement with AstraZeneca to Deliver Innovative Therapies for hypercholesterolemia
Shots:
- Cholesgen will be eligible to receive initial fees as well as a pre-defined license package for each qualified drug candidate nominated by AstraZeneca to progress into clinical development
- The partnership focuses to validate genetic drug targets and advance therapeutic molecules into clinical development. It will use complementary strengths and focus on selected targets from Cholesgen's early-stage portfolios
- AstraZeneca and Cholesgen scientists will collaborate closely on target validation and deliver the selected drug candidates under the governance of a Joint Research Committee while AstraZeneca has the first option to advance them into clinical development
Ref: PRNewswire | Image: Astrazeneca
Related News:- Merck and AstraZeneca's Lynparza (Olaparib) Receive NICE Recommendation for Maintenance Treatment of BRCA-Mutated Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
